Effectiveness of the AML-XH-99-M3 protocol for treatment of acute promyelocytic leukemia in children.
- Author:
Jing CHEN
1
;
Long-Jun GU
;
Jing-Yan TANG
;
Hui-Liang XUE
;
Ci PAN
;
Qi-Dong YE
;
Hua JIANG
;
Lu DONG
;
Min ZHOU
;
Yao-Ping WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Child; Child, Preschool; Cytarabine; administration & dosage; Daunorubicin; administration & dosage; Etoposide; administration & dosage; Female; Humans; Infant; Leukemia, Promyelocytic, Acute; drug therapy; mortality; Male; Tretinoin; administration & dosage
- From: Chinese Journal of Contemporary Pediatrics 2008;10(3):329-332
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the effectiveness of AML-XH-99-M3 protocol for treatment of acute promyelocytic leukemia (APL) in children.
METHODSThirty-three children with APL received AML-XH-99-M3 protocol treatment. The event-free survival (EFS), disease-free survival (DFS), and overall survival (OS) were evaluated by the Kaplan-Meier medthod with SPSS13.0 software.
RESULTSThirty patients (90.9%) achieved a complete remission (CR) after one course of treatment. The total CR rate was 100%. Six patients (18.2%) relapsed in an average of 29.17 months (16-38 months). Two patients (6.1%) died. The 7-year EFS and DFS in the 30 patients were 73.4+/-9.4%. The overall survival rate was 91.2+/-6.0%. The difference of EFS was observed in patients receiving intermittent all-trans-retinoic acid (ATRA) administration or not in the maintenance therapy (88.9+/-10.5% vs 62.5+/-13.6%) (P<0.05).
CONCLUSIONSThe AML-XH-99-M3 protocol for the treatment of APL produced a higher CR rate and higher EFS, DFS and OS rates in children. Intermittent administration of ATRA in the maintenance therapy can improve EFS rate.
